Classification of GBA1 variants and their impact on Parkinson's disease: an in silico score analysis.

GBA1 变异体的分类及其对帕金森病的影响:计算机评分分析

阅读:17
作者:Lanore Aymeric, Tesson Christelle, Basset Aymeric, Lejeune François-Xavier, Cogan Guillaume, Mangone Graziella, Sambin Sara, Bertille Nathalie, Anheim Mathieu, Arnulf Isabelle, Ansquer Solène, Brandel Jean-Philippe, Brefel-Courbon Christine, Defebvre Luc, Drapier Sophie, Eusebsio Alexandre, Fabbri Margherita, Giordana Caroline, Hainque Elodie, Lehericy Stephane, Marques Ana, Moreau Caroline, Moro Elena, Ory Fabienne, Rolland Anne-Sophie, Thobois Stéphane, Vidailhet Marie, Devos David, Mariani Louise-Laure, Lesage Suzanne, Brice Alexis, Corvol Jean-Christophe
Bi-allelic pathogenic GBA1 variants cause Gaucher disease (GD), whereas certain heterozygous missense variants increase the risk of Parkinson's disease (PD), although the underlying mechanisms are unclear. Here, we classified GBA1 missense variants using predictive and structural scores, and analysed their associations with enzyme activity, Saposin C (SapC) interaction and PD progression in 639 patients with heterozygous GBA1 variants from five cohorts. Principal component analysis (PCA) identified two components: PC1, associated with reduced β-glucocerebosidase activity, the GD clinical severity classification, younger age at PD diagnosis, and faster cognitive and motor decline; and PC2, associated with surface-exposed, flexible regions involved in SapC interactions, younger age at PD diagnosis, and slightly with motor decline. These findings highlight that impaired SapC interactions, in addition to reduced activity, may contribute to PD severity in GBA1 variant carriers. This is relevant for therapeutic approaches aimed at stabilizing β-glucocerebosidase or enhancing its enzymatic activity in PD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。